51 results on '"Belhadj K"'
Search Results
2. Les amyloses cardiaques : état des lieux en 2022
3. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
4. P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
5. P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
6. P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
7. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
8. Existence and multiplicity results for fractional p(x)-Laplacian Dirichlet problem
9. POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France
10. Liste des collaborateurs
11. Lymphomes : principes thérapeutiques et imagerie post-thérapeutique
12. S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS
13. PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY
14. PS1410 DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT
15. CLINICAL, IMMUNOPHENOTYPIC AND GENETIC CHARACTERISTICS OF AGGRESSIVE (NON-BURKITT) B-CELL LYMPHOMA IN A REAL LIFE COHORT
16. RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN (R-GemOx) IN REFRACTORY/RELAPSED (R/R) DLBCL. A REAL LIFE STUDY IN PATIENTS INELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION
17. PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
18. Single or combined cardiac transplantation for Cardiac Amyloidosis. A report from the French National Referral Center for Cardiac Amyloidosis
19. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)
20. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
21. Continuous Lenalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and Renal Impairment in the First Trial
22. A Prospective Phase II Trial of Lenalidomide and Dexamethasone (Len-Dex) in POEMS Syndrome
23. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis
24. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study
25. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients
26. Existe-t’il encore des TRALI d’origine immunologique en 2011 ?
27. Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma
28. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA
29. Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL).
30. Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.
31. IRM corps entier dynamique dans l’evaluation de la reponse therapeutique des patients presentant un myelome
32. Transmesocolic internal herniation: a rare case of small bowel obstruction, “the Marrakesh hernia”
33. 96 PET imaging of non-Hodgkin lymphoma: defining methodologies for early prediction of response
34. Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003–3)
35. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
36. Étude électrophysiologique par voie transœsophagienne chez des enfants de moins de 11 ans, non sédatés, ayant un syndrome de Wolff-Parkinson-White
37. Successful Long-Term Outcome of the First Combined Heart and Kidney Transplant in a Patient with Systemic AL Amyloidosis
38. Place de l’imagerie fonctionnelle
39. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
40. Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma
41. Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients
42. Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma
43. Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients
44. Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma
45. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study
46. 033 Étude de la pratique des sutures en médecine de ville et aux urgences hospitalières comme traceur d’activité de la traumatologie courante
47. Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients
48. T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis
49. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients
50. Prise en charge des hémorragies digestives aiguës hautes : utilisation des médicaments à visée hémostatiqueHaemostatic drugs should be considered for the initial treatment of acute gastrointestinal bleeding.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.